METASTATIC BREAST CANCER

This study tested whether adding an experimental drug called samuraciclib to the standard hormone therapy fulvestrant could better control advanced breast cancer that has stopped responding to prior treatments. It involved 60 adults with hormone receptor-positive, HER2-negative b…

This early-phase study tested whether combining a precise form of radiation (stereotactic radiosurgery) with an immunotherapy drug (nivolumab) is safe and can help control breast cancer that has spread to the brain. It involved 14 adults with metastatic breast cancer and brain tu…

This study followed 80 Egyptian women with HER2-positive breast cancer to see how well anti-HER2 drugs work in real-world treatment. Researchers observed patients receiving either single drugs or drug combinations as part of their standard care, tracking survival, side effects, a…

This study tested whether delivering the breast cancer drug trastuzumab (Herceptin) directly into the spinal fluid could help patients whose cancer had spread to the membranes around the brain and spinal cord. The trial involved 34 people with advanced HER2-positive breast cancer…

This study tested a combination of two oral drugs, palbociclib and tamoxifen, as the first treatment for women with advanced hormone-positive breast cancer that had spread. The goal was to see how long the treatment could control the cancer's growth and how well patients tolerate…

This study tested whether a specific lab test, called the RAD51-foci score, could predict which patients with advanced HER2-negative breast cancer would benefit most from the drug olaparib. It involved 65 patients, some with known genetic mutations and some without, to see if the…

This large study tested whether switching hormone therapy early—based on detecting specific cancer mutations in blood tests—could help women with advanced breast cancer live longer without their cancer worsening. Over 1,000 women whose cancer had spread participated. Researchers …

This study tested whether adding precise, high-dose radiation to standard drug therapy could help people with breast cancer that has spread to only a few other body parts. It aimed to see if this combined approach could keep the cancer from growing longer and improve patients' qu…

This study tested whether combining two drugs, samuraciclib and elacestrant, is safe and effective for people with advanced hormone-positive, HER2-negative breast cancer that has progressed on standard therapy. It involved 49 adult participants internationally. The trial first ai…

This early-stage study tested adding a new drug called ipatasertib to two standard medications (trastuzumab and pertuzumab) for people with advanced HER2-positive breast cancer that also has a specific genetic change (PIK3CA mutation). The main goal was to find the safest and mos…

This study tested whether combining three medications—olaparib, palbociclib, and fulvestrant—is safe for people with advanced breast cancer that is hormone-sensitive and has a BRCA gene mutation. The main goal was to check for side effects and see how long patients lived without …

This study tested a new drug called U3-1402 in 121 patients whose breast cancer had spread or was locally advanced. The main goal was to see if the drug was safe and if it could shrink tumors or stop the cancer from growing for at least six months. Researchers also looked at how …

This study tested a special therapy program designed to help people with advanced brain cancer manage the emotional distress that comes with their diagnosis. Researchers compared the therapy, called CALM, to standard care in 60 patients. The main goal was to see if the program wa…

This study observed how patients with advanced HER2-positive or HER2-low breast cancer used the drug trastuzumab deruxtecan (T-DXd) in routine Canadian clinics. Researchers tracked 22 patients to see how often treatment was stopped early or doses were changed, and how long patien…

This study aimed to understand how the breast cancer drug palbociclib is actually used in everyday medical practice in Israel. It observed 559 adult patients whose breast cancer had spread and who were already prescribed this drug as part of their standard care. The goal was to c…

This study aimed to understand how a specific breast cancer drug combination (palbociclib) is used and how well it works in real-world medical practice across Africa and the Middle East. Researchers observed 185 patients with advanced breast cancer who were already prescribed thi…

This study aimed to learn directly from patients about their experiences taking a specific drug combination (capivasertib + fulvestrant) for advanced breast cancer. Researchers interviewed 48 people who had taken the treatment to understand their attitudes, dosing experiences, an…

This study analyzed existing medical records from over 20,000 women with metastatic breast cancer in France. Researchers examined real-world survival data to find faster, reliable ways to measure if cancer treatments are working. The goal is to help future clinical trials get res…

This study aimed to understand whether certain unusual cells found in the blood of people with metastatic breast cancer actually come from their tumors. Researchers collected blood samples from 60 patients before they started new cancer treatments to analyze these cells. The goal…